• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

cGMP/PKG 通路通过延迟再灌注期间细胞内酸中毒的正常化来介导心肌后处理保护作用。

cGMP/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion.

机构信息

Laboratory of Experimental Cardiology, Vall d'Hebron University Hospital and Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.

出版信息

J Mol Cell Cardiol. 2011 May;50(5):903-9. doi: 10.1016/j.yjmcc.2011.02.013. Epub 2011 Feb 26.

DOI:10.1016/j.yjmcc.2011.02.013
PMID:21362429
Abstract

Ischemic postconditioning has been demonstrated to limit infarct size in patients, but its molecular mechanisms remain incompletely understood. Low intracellular pH (pHi) inhibits mitochondrial permeability transition, calpain activation and hypercontracture. Recently, delayed normalization of pHi during reperfusion has been shown to play an important role in postconditioning protection, but its relation with intracellular protective signaling cascades is unknown. The present study investigates the relation between the rate of pHi normalization and the cGMP/PKG pathway in postconditioned myocardium. In isolated Sprague-Dawley rat hearts submitted to transient ischemia both, postconditioning and acidic reperfusion protocols resulted in a similar delay in pHi recovery measured by (31)P-NMR spectroscopy (3.6±0.2min and 3.5±0.2min respectively vs. 1.4±0.2min in control group, P<0.01) and caused equivalent cardioprotection (48% and 41% of infarct reduction respectively, P<0.01), but only postconditioning increased myocardial cGMP levels (P=0.02) and activated PKG. Blockade of cGMP/PKG pathway by the addition of the guanylyl cyclase inhibitor ODQ or the PKG inhibitor KT5823 during reperfusion accelerated pHi recovery and abolished cardioprotection in postconditioned hearts, but had no effect in hearts subjected to acidic reperfusion suggesting that PKG signaling was upstream of delayed pHi normalization in postconditioned hearts. In isolated cardiomyocytes the cGMP analog 8-pCPT-cGMP delayed Na(+)/H(+)-exchange mediated pHi normalization after acidification induced by a NH(4)Cl pulse. These results demonstrate that the cGMP/PKG pathway contributes to postconditioning protection at least in part by delaying normalization of pHi during reperfusion, probably via PKG-dependent inhibition of Na(+)/H(+)-exchanger.

摘要

缺血后处理已被证实可缩小患者的梗塞面积,但其中的分子机制尚不完全清楚。细胞内低 pH 值(pHi)可抑制线粒体通透性转换、钙蛋白酶激活和过度收缩。最近的研究表明,再灌注期间 pHi 的延迟正常化在缺血后处理保护中发挥重要作用,但它与细胞内保护信号级联的关系尚不清楚。本研究探讨了 pHi 正常化速率与缺血后处理心肌中环鸟苷酸/蛋白激酶 G(cGMP/PKG)途径之间的关系。在经历短暂缺血的分离的 Sprague-Dawley 大鼠心脏中,缺血后处理和酸性再灌注方案均导致 pHi 恢复的测量值(通过 31P-NMR 光谱)相似延迟(分别为 3.6±0.2min 和 3.5±0.2min,而对照组为 1.4±0.2min,P<0.01),并引起等效的心脏保护作用(分别减少 48%和 41%的梗塞面积,P<0.01),但只有缺血后处理增加了心肌 cGMP 水平(P=0.02)并激活了 PKG。在再灌注期间加入鸟苷酸环化酶抑制剂 ODQ 或 PKG 抑制剂 KT5823 阻断 cGMP/PKG 途径可加速缺血后处理心脏的 pHi 恢复并消除心脏保护作用,但对经历酸性再灌注的心脏没有影响,提示 PKG 信号转导位于缺血后处理心脏中 pHi 延迟正常化的上游。在分离的心肌细胞中,cGMP 类似物 8-pCPT-cGMP 可延迟由 NH4Cl 脉冲诱导的酸化后 Na+/H+交换介导的 pHi 正常化。这些结果表明,cGMP/PKG 途径通过至少部分通过再灌注期间 pHi 的延迟正常化来促进缺血后处理保护,可能通过 PKG 依赖性抑制 Na+/H+交换器。

相似文献

1
cGMP/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion.cGMP/PKG 通路通过延迟再灌注期间细胞内酸中毒的正常化来介导心肌后处理保护作用。
J Mol Cell Cardiol. 2011 May;50(5):903-9. doi: 10.1016/j.yjmcc.2011.02.013. Epub 2011 Feb 26.
2
Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium.再灌注期间细胞内酸中毒的延迟恢复可防止钙蛋白酶激活,并决定了后适应心肌中的保护作用。
Cardiovasc Res. 2009 Jan 1;81(1):116-22. doi: 10.1093/cvr/cvn260. Epub 2008 Oct 1.
3
Effect of acidic reperfusion on prolongation of intracellular acidosis and myocardial salvage.酸性再灌注对细胞内酸中毒延长及心肌挽救的影响。
Cardiovasc Res. 2008 Mar 1;77(4):782-90. doi: 10.1093/cvr/cvm082. Epub 2007 Dec 4.
4
Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation.环鸟苷酸-蛋白激酶 G 信号通路在模拟缺血/再灌注损伤的新生大鼠心肌细胞保护中的作用。
Basic Res Cardiol. 2010 Sep;105(5):643-50. doi: 10.1007/s00395-010-0097-0. Epub 2010 Mar 28.
5
Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury.心肌再灌注损伤细胞模型中cGMP介导的保护机制。
Cardiovasc Res. 2005 Apr 1;66(1):123-31. doi: 10.1016/j.cardiores.2005.01.007.
6
Delayed phospholamban phosphorylation in post-conditioned heart favours Ca2+ normalization and contributes to protection.心肌后处理延迟磷蛋白磷酸化有利于钙正常化,并有助于保护。
Cardiovasc Res. 2014 Sep 1;103(4):542-53. doi: 10.1093/cvr/cvu163. Epub 2014 Jun 27.
7
Gender-related difference of sevoflurane postconditioning in isolated rat hearts: focus on phosphatidylinositol-3-kinase/Akt signaling.七氟醚后处理在大鼠离体心脏中的性别相关差异:聚焦于磷脂酰肌醇-3-激酶/蛋白激酶 B 信号通路。
J Surg Res. 2011 Sep;170(1):e3-9. doi: 10.1016/j.jss.2011.04.035. Epub 2011 May 17.
8
Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling.心肌后处理中 cGMP/蛋白激酶 G 通路的激活依赖于氧化应激的减少和内皮型一氧化氮合酶偶联的保留。
J Am Heart Assoc. 2013 Jan 2;2(1):e005975. doi: 10.1161/JAHA.112.005975.
9
Hydrogen sulfide regulates Na+/H+ exchanger activity via stimulation of phosphoinositide 3-kinase/Akt and protein kinase G pathways.硫化氢通过激活磷脂酰肌醇 3-激酶/蛋白激酶 G 途径调节 Na+/H+交换体活性。
J Pharmacol Exp Ther. 2011 Nov;339(2):726-35. doi: 10.1124/jpet.111.184754. Epub 2011 Aug 24.
10
Limited effects of post-ischemic NHE blockade on [Na+]i and pHi in rat hearts explain its lack of cardioprotection.缺血后钠氢交换体阻断对大鼠心脏肌浆网[Na⁺]i和pHi的影响有限,这解释了其缺乏心脏保护作用的原因。
Cardiovasc Res. 2004 Feb 15;61(3):522-9. doi: 10.1016/j.cardiores.2003.07.005.

引用本文的文献

1
Cardioprotection Reloaded: Reflections on 40 Years of Research.心脏保护重装上阵:40年研究回顾
Antioxidants (Basel). 2025 Jul 18;14(7):889. doi: 10.3390/antiox14070889.
2
Influence of Soluble Guanylate Cyclase on Cardiac, Vascular, and Renal Structure and Function: A Physiopathological Insight.可溶性鸟苷酸环化酶对心脏、血管和肾脏结构与功能的影响:生理病理学见解
Int J Mol Sci. 2025 May 9;26(10):4550. doi: 10.3390/ijms26104550.
3
UHPLC-Q-Orbitrap HRMS and network analysis to explore the mechanisms of QiShenYiQi dripping pill for treating myocardial infarction.
超高效液相色谱-四极杆-轨道阱高分辨质谱联用技术及网络分析探究芪参益气滴丸治疗心肌梗死的机制
Front Pharmacol. 2024 Nov 1;15:1443560. doi: 10.3389/fphar.2024.1443560. eCollection 2024.
4
Initial Despair and Current Hope of Identifying a Clinically Useful Treatment of Myocardial Reperfusion Injury: Insights Derived from Studies of Platelet P2Y Antagonists and Interference with Inflammation and NLRP3 Assembly.心肌再灌注损伤的临床有效治疗方法的最初绝望与当前希望:来自血小板 P2Y 拮抗剂研究和炎症及 NLRP3 组装干扰的见解。
Int J Mol Sci. 2024 May 17;25(10):5477. doi: 10.3390/ijms25105477.
5
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives.磷酸二酯酶5抑制剂的进展:揭示当前与未来展望
Pharmaceuticals (Basel). 2023 Sep 6;16(9):1266. doi: 10.3390/ph16091266.
6
An Overview of the Molecular Mechanisms Associated with Myocardial Ischemic Injury: State of the Art and Translational Perspectives.心肌缺血损伤相关分子机制概述:现状及转化研究视角。
Cells. 2022 Mar 30;11(7):1165. doi: 10.3390/cells11071165.
7
Molecular Signaling to Preserve Mitochondrial Integrity against Ischemic Stress in the Heart: Rescue or Remove Mitochondria in Danger.分子信号在心脏对抗缺血应激中保护线粒体完整性:拯救或清除危险的线粒体。
Cells. 2021 Nov 27;10(12):3330. doi: 10.3390/cells10123330.
8
Sex and Response to Cardioprotective Conditioning Maneuvers.性别与心脏保护预处理措施的反应
Front Physiol. 2021 May 14;12:667961. doi: 10.3389/fphys.2021.667961. eCollection 2021.
9
The role of mitochondrial reactive oxygen species, NO and H S in ischaemia/reperfusion injury and cardioprotection.线粒体活性氧、NO 和 H₂S 在缺血/再灌注损伤及心脏保护中的作用。
J Cell Mol Med. 2020 Jun;24(12):6510-6522. doi: 10.1111/jcmm.15279. Epub 2020 May 8.
10
Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease.5型磷酸二酯酶抑制剂在心血管疾病中的既定及新出现的治疗用途。
Br J Pharmacol. 2020 Dec;177(24):5467-5488. doi: 10.1111/bph.14920. Epub 2020 Feb 4.